KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
MedComm · 2026-10 · 7 (10)
DOI: 10.1002/mco2.71050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 06.10.2026. Verfasst von Jiaying Cai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical Academy Hangzhou Medical College (HMC) Hangzhou Zhejiang People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
KRAS is one of the most frequently altered oncogenic drivers across human solid tumors and has long represented a central challenge in precision oncology. The clinical success of covalent KRAS G12C inhibitors has transformed a historically “undruggable” target into a tractable therapeutic class, but durable benefit remains limited by adaptive feedback, acquired resistance, co‐mutation context, and tumor‐lineage‐specific barriers. A major unresolved question is how to extend this success across diverse KRAS alleles and cancer types. This review summarizes the molecular epidemiology and therapeutic landscape of KRAS‐mutant cancers, with emphasis on non‐small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. We compare G12C‐directed therapy with emerging G12D‐, G12V‐, and pan‐KRAS strategies and dissect resistance architectures involving EGFR feedback, RTK/MAPK/PI3K pathway reactivation, phenotypic plasticity, stromal constraints, and immune or metabolic adaptation. We further discuss resistance‐informed combination therapy, targeted protein degraders, immune‐based approaches, antibody–drug conjugates, biomarker‐guided sequencing, and strategies for rare KRAS variants. Particular attention is given to how allele identity, tumor lineage, and adaptive signaling jointly shape therapeutic vulnerability. By framing KRAS therapy through the “same mutation, different outcomes” paradigm, this review provides a context‐informed roadmap for extending KRAS‐directed precision oncology beyond G12C monotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Medical Academy Hangzhou Medical College (HMC) Hangzhou Zhejiang People's Republic of China.
- Department of Anesthesiology Zhejiang Cancer Hospital Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Hangzhou Zhejiang People's Republic of China.
- Department of Thyroid Surgery Zhejiang Cancer Hospital Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Hangzhou Zhejiang People's Republic of China.
- Department of Gynecologic Oncology Zhejiang Cancer Hospital Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Hangzhou Zhejiang People's Republic of China.
- Department of Thoracic Surgery Zhejiang Cancer Hospital Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Hangzhou Zhejiang People's Republic of China.
- College of Traditional Chinese Medicine and Pharmacy Jinggangshan University Ji'an Jiangxi People's Republic of China.
Zitieren
APA
Cai, J., Wu, Y., Jia, X., Yang, L., Yang, W., Lu, W., Huang, Z., Pan, Y., Fei, Z., Ru, J., Zhao, J., Shen, J., Luo, T., Chen, D., Yu, H., Deng, H., Zeng, J., Jiang, W., & Wu, L. (2026). KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. MedComm, 7(10). https://doi.org/10.1002/mco2.71050
Vancouver
Cai J, Wu Y, Jia X, Yang L, Yang W, Lu W, et al. KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. MedComm. 2026;7(10). doi:10.1002/mco2.71050
BibTeX
@article{Cai2026,
author = {Cai, Jiaying and Wu, Yimin and Jia, Xing and Yang, Li and Yang, Wenjun and Lu, Weishan and Huang, Zhiye and Pan, Yang and Fei, Zixuan and Ru, Junnan and Zhao, Jiazheng and Shen, Jue and Luo, Taobo and Chen, Da and Yu, Haihong and Deng, Haihan and Zeng, Jian and Jiang, Wenmei and Wu, Leilei},
title = {KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine},
journal = {MedComm},
year = {2026},
volume = {7},
number = {10},
doi = {10.1002/mco2.71050}
}
EUVIMED